Projet EFFECT (Horizon Europe, appel à projets 2023)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

The EFFecT Doctoral Training (DN) Network responds to the evolving landscape of RNA-based therapeutics and in particular antisense oligonucleotides (ASO). Over the last 25 years, only 21 antisense nucleic acid-based molecules have been approved by the FDA or/and EMA. However, the field is now at the tipping point of maturity to achieve regular translation from bench to bed side, provided that certain obstacles are successfully addressed. Our consortium involves experts from academia, industry, and non-profit organizations across nine European countries with first-hand experience in the successful translation of this new technology and in-depth knowledge of the remaining hurdles for its success. With leading scientists at different career stages, EFFecT’s core is form by nine academic and three industrial partners. EFFecT's objectives include addressing tissue-specific delivery challenges, imparting knowledge on diverse ASO modalities, and creating a roadmap for ASO therapeutics in Europe. The network's composition leverages over 20 years of experience in nucleic acid drug development, and was born from the successful COST Action "Delivery of Antisense RNA ThERapeutics" (DARTER). The EFFecT training network ensures a comprehensive education for Doctoral Candidates through knowledge exchange, secondments, research workshops and dissemination. This network is expanded with the collaborations of experts in communication, intellectual property, and open science that will train the DCs in good scientific practices. By addressing training gaps and fostering collaborations, EFFecT is poised to deliver the next generation of experts in this up-and coming field, elevating Europe's visibility and competitiveness in antisense RNA therapeutics.

Mots clés : antisense oligonucleotides rna based therapies genetic therapies nucleic acids delivery model systems drug development

Participants :
- Université de Versailles Saint-Quentin-en-Yvelines (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 282693.6 €
- Institut servier d'innovation therapeutique (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 282693.6 €
- Radboud University Medical Centre (Pays-Bas) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 274370.4 €
- AstraZeneca (Sweden) (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 293709.6 €
- Université de Gand (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 262620.0 €
- Institut de Recherche et d’Innovation en Santé de l’Université de Porto (Portugal) — Partner, beneficiary, Recherche, subvention : 243403.2 €
- Stichting dutch antisense therapeutics (Pays-Bas) — Partner, associated partner, Autres, subvention : 0.0 €
- University College de Londres (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Institut Karolinska (Suède) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université autonome de Madrid (Espagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 251971.2 €
- Astherna bv (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 274370.4 €
- Université Paris-Saclay (France) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université Radboud de Nimègue (Pays-Bas) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Stichting duchenne data foundation (Pays-Bas) — Partner, associated partner, Autres, subvention : 0.0 €
- Université de Trente (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 259437.6 €
- Leiden University Medical Center (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274370.4 €
- Asociacion instituto de investigacion sanitaria biobizkaia (Espagne) — Partner, beneficiary, Recherche, subvention : 251971.2 €
- Institut de Recherche et d’Innovation en Santé de l’Université de Porto (Portugal) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Fondazione hub innovazione trentino (Italie) — Partner, associated partner, Recherche, subvention : 0.0 €
- Université du Pays basque (Espagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €